Clene Inc. (NASDAQ:CLNN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Clene Inc. (NASDAQ:CLNN) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $33.25.

Several analysts have issued reports on CLNN shares. Weiss Ratings cut Clene from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 27th. HC Wainwright reaffirmed a “buy” rating on shares of Clene in a research note on Monday, August 17th. Finally, Roth Capital reiterated a “buy” rating on shares of Clene in a report on Thursday, May 14th.

Hedge Funds Weigh In On Clene

Institutional investors have recently bought and sold shares of the company. PEAK6 LLC acquired a new position in Clene in the 4th quarter valued at about $294,000. State Street Corp grew its stake in shares of Clene by 138.4% in the 4th quarter. State Street Corp now owns 29,801 shares of the company’s stock valued at $175,000 after buying an additional 17,300 shares during the period. Ensign Peak Advisors Inc increased its holdings in shares of Clene by 668.6% during the 4th quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock worth $671,000 after buying an additional 99,481 shares during the last quarter. SymBiosis Capital Partners LLC acquired a new stake in shares of Clene during the 4th quarter worth approximately $4,523,000. Finally, Geode Capital Management LLC raised its position in shares of Clene by 8.0% during the 4th quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock valued at $482,000 after buying an additional 6,090 shares during the period. 23.28% of the stock is owned by hedge funds and other institutional investors.

Clene Price Performance

Shares of Clene stock opened at $3.85 on Friday. The stock’s 50 day simple moving average is $5.15 and its 200-day simple moving average is $5.62. The stock has a market cap of $49.47 million, a P/E ratio of -1.10 and a beta of 0.95. Clene has a 1-year low of $3.72 and a 1-year high of $13.50.

Clene (NASDAQ:CLNN) last posted its quarterly earnings results on Friday, August 14th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.71). The company had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.06 million. As a group, research analysts expect that Clene will post -1.7 EPS for the current fiscal year.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).